Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In ...

A recent study published in the Journal for Immunotherapy of Cancer has revealed a promising new approach for the treatment ...

Chinese investigators have published data from studies investigating CYT-997 for the treatment of hypertrophic scars. CYT-997 is a tubulin polymerization inhibitor that reached phase II clinical ...

The first systematic whole genome sequencing study of how chemotherapy damages healthy tissues has shown that many, but not ...

The oxidase, cytochrome c, assembly 1-like (OXA1L) gene plays a key role in inserting and assembling proteins in the inner ...

Field Medical Inc. continues to reap funding from investors for its pulsed field ablation (PFA) system with a $35 million ...

All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, ...

Researchers at Washington University reported the preclinical validation of [18F]FQ-NeuroROS, a redox-sensitive reporter ...

Actinium Pharmaceuticals Inc. recently presented data on ATNM-400, a new antibody radioconjugate that uses actinium-225 ...

Agonists of immune checkpoint modulators for treating autoimmune and inflammatory disorders have shown high potential in ...

The U.S. Health and Human Services and the Justice Departments are bringing more resources to their crack down on False ...

Brightpath Biotherapeutics Co. Ltd.’s iPS cell-derived BCMA CAR-natural killer T cell therapy candidate has been awarded orphan drug designation by the FDA for the treatment of multiple myeloma.